← ANALYST RATINGS · TIPRANKS
BillionToOne, Inc. Class A (BLLN): analyst forecast and price target
Analyst consensus
Strong Buy7 Buy0 Hold0 Sell
Ratings of 7 analysts in the last 3 months · top analysts only12-month forecast
Based on 7 price targets given in the last 3 months, the average target is $129, the highest $145, the lowest $120. The average is +31.3% from the last price of $98.12.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI PerPlexity Medical - Diagnostics and ResearchPerPlexity SonarPro | TipRanks - PerPlexity | $106 → $107+0.9% | Hold | +9.1% | Downgrade | 17.10.26on TipRanks 12:05 | — | |
| AI xAi Medical - Diagnostics and ResearchxAI Grok-3 | TipRanks - xAI | $102 → $108+5.9% | Buy | +10.1% | Upgrade | 15.10.26on TipRanks 12:05 | — | |
| AI DeepSeek Medical - Diagnostics and ResearchDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $104 → $109+4.8% | Buy | +11.1% | Reiterated | 15.10.26on TipRanks 12:05 | — | |
| AI OpenAI Medical - Diagnostics and ResearchOpenAI 5.2 | TipRanks - OpenAI | $103 → $109+5.8% | Buy | +11.1% | Reiterated | 15.10.26on TipRanks 12:05 | — | |
| AI Anthropic Medical - Diagnostics and ResearchAnthropic Opus-4.5 | TipRanks - Anthropic | $102 → $108+5.9% | Buy | +10.1% | Upgrade | 15.10.26on TipRanks 12:05 | — | |
| AI Google Medical - Diagnostics and ResearchGemini 3-pro | TipRanks - Google | $105 → $111+5.7% | Buy | +13.1% | Reiterated | 15.10.26on TipRanks 12:05 | — | |
| Subbu Nambi★★★★★★★★★★#281 · hits 72% · avg +34.4% | Guggenheim | $125 → $128+2.4% | Buy | +30.5% | Reiterated | 01.10.26on TipRanks 08:30 | −0.8%next day −0.6% · 5 days −11.1% | ↗ |
| Kyle Mikson CFA★★★★★★★★★★#2814 · hits 38% · avg +5.9% | Canaccord Genuity | $120 | Buy | +22.3% | Initiated | 02.09.26on TipRanks 06:45 | +3.7%next day +2.4% · 5 days +3.4% | ↗ |
| Matt Larew★★★★★★★★★★#816 · hits 63% · avg +19.3% | William Blair | — | Buy | — | Reiterated | 06.08.26on TipRanks 13:35 | −38.7%next day +1.3% · 5 days +1.4% | ↗ |
| Daniel Arias★★★★★★★★★★#1848 · hits 50% · avg +8.0% | Stifel Nicolaus | $145 | Buy | +47.8% | Reiterated | 06.08.26on TipRanks 12:45 | −38.7%next day +1.3% · 5 days +1.4% | ↗ |
| Casey Woodring★★★★★★★★★★#2489 · hits 62% · avg +8.2% | J.P. Morgan | $130 | Buy | +32.5% | Reiterated | 06.08.26on TipRanks 07:20 | −38.7%next day +1.3% · 5 days +1.4% | ↗ |
| David Westenberg★★★★★★★★★★#602 · hits 56% · avg +17.3% | Piper Sandler | $120 | Buy | +22.3% | Reiterated | 06.08.26on TipRanks 07:01 | −38.7%next day +1.3% · 5 days +1.4% | ↗ |
| Mark Massaro★★★★★★★★★★#2635 · hits 40% · avg +5.7% | BTIG | $142 → $130−8.5% | Buy | +32.5% | Reiterated | 06.08.26on TipRanks 06:00 | −38.7%next day +1.3% · 5 days +1.4% | ↗ |
| Tycho Peterson★★★★★★★★★★#1097 · hits 57% · avg +9.8% | Jefferies | $117 | Hold | +19.2% | Initiated | 01.12.25on TipRanks 04:45 | −12.7%next day +1.5% · 5 days −7.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering BillionToOne, Inc. Class A
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $129 at a price of $106 (+21.0%); now: $129 at $98.12 (+31.3%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 2 | 1 | 1 | 1 | 1 |
| Buy | 8 | 7 | 9 | 7 | 7 | 6 |
| Hold | 2 | 1 | 2 | 2 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 04.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.15 (from $0.09 to $0.21). Last quarter: $0.15.
Sales
Next quarter’s sales estimate — $116M (from $112M to $118M). Last quarter: $109M.
Best top-analyst consensus in the sector · General
About BillionToOne, Inc. Class A
- CEO: Oguzhan Atay
- Employees: 713
- 1035 O’Brien Drive, Menlo Park, CA, 94025, US
- www.billiontoone.com
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
Data from the stock’s TipRanks forecast page, read 99 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗